Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 6, 2019
Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin AgentsRaffaella Gentilella, Irene Romera, Claudia Nicolay, et al.
Diabetes, Obesity & Metabolism|August 9, 2019
Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass indexRaffaella Gentilella, Giorgio Sesti, Luis Vazquez, et al.
BMC Psychiatry|February 13, 2013
Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysisIrene Romera, Víctor Pérez, Antonio Ciudad, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 17, 2022
Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical ConsiderationsJosé L Górriz, Irene Romera, Amelia Cobo, et al.
Advances in Therapy|May 19, 2025
Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D StudyEmilio Ortega, Jennifer Redondo-Antón, Silvia Díaz-Cerezo, et al.
Journal of Diabetes and Its Complications|March 30, 2020
Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1cIrene Romera, Ignacio Conget, Luis Alberto Vazquez, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 30, 2019
Clinical Inertia in Poorly Controlled Type 2 Diabetes Mellitus Patients with Obesity: An Observational Retrospective StudyIrene Romera, Silvia Díaz, Antoni Sicras-Mainar, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|September 1, 2016
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitusIrene Romera, Francisco Javier Ampudia-Blasco, Antonio Pérez, et al.
Pageof 5